Oppenheimer Asset Management Inc. Has $5.39 Million Holdings in Insulet Corporation (NASDAQ:PODD)

Oppenheimer Asset Management Inc. lifted its stake in Insulet Corporation (NASDAQ:PODD - Free Report) by 5.7% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 20,516 shares of the medical instruments supplier's stock after buying an additional 1,114 shares during the period. Oppenheimer Asset Management Inc.'s holdings in Insulet were worth $5,388,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. SBI Securities Co. Ltd. acquired a new position in shares of Insulet in the 4th quarter worth approximately $36,000. Itau Unibanco Holding S.A. acquired a new position in shares of Insulet in the 4th quarter worth approximately $42,000. SRS Capital Advisors Inc. raised its holdings in shares of Insulet by 43.1% in the 4th quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier's stock worth $49,000 after buying an additional 56 shares in the last quarter. Assetmark Inc. raised its holdings in shares of Insulet by 1,447.1% in the 4th quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier's stock worth $69,000 after buying an additional 246 shares in the last quarter. Finally, Coppell Advisory Solutions LLC raised its holdings in shares of Insulet by 135.0% in the 4th quarter. Coppell Advisory Solutions LLC now owns 282 shares of the medical instruments supplier's stock worth $74,000 after buying an additional 162 shares in the last quarter.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the company. Wolfe Research raised Insulet from a "peer perform" rating to an "outperform" rating and set a $350.00 price target on the stock in a research note on Tuesday, May 13th. Royal Bank Of Canada started coverage on Insulet in a research note on Thursday, March 6th. They issued an "outperform" rating and a $340.00 price target on the stock. Wall Street Zen downgraded Insulet from a "buy" rating to a "hold" rating in a research note on Saturday, June 14th. Oppenheimer raised their price objective on Insulet from $312.00 to $324.00 and gave the company an "outperform" rating in a report on Friday, May 9th. Finally, Citigroup reaffirmed a "buy" rating and set a $380.00 price target (up from $320.00) on shares of Insulet in a research report on Thursday, May 22nd. Four equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $321.00.

Insulet Stock Performance

Shares of NASDAQ:PODD traded up $3.60 during trading on Thursday, reaching $309.83. 628,466 shares of the stock were exchanged, compared to its average volume of 714,534. Insulet Corporation has a 12 month low of $173.00 and a 12 month high of $329.33. The firm has a market cap of $21.81 billion, a PE ratio of 55.72, a PEG ratio of 2.77 and a beta of 1.37. The stock has a 50-day moving average price of $295.11 and a 200-day moving average price of $277.04. The company has a current ratio of 4.47, a quick ratio of 3.63 and a debt-to-equity ratio of 1.21.

Insulet (NASDAQ:PODD - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $1.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.81 by $0.21. The business had revenue of $569.00 million during the quarter, compared to analysts' expectations of $543.20 million. Insulet had a return on equity of 22.25% and a net margin of 18.29%. The firm's revenue for the quarter was up 28.8% compared to the same quarter last year. During the same period in the previous year, the company posted $0.73 earnings per share. Research analysts expect that Insulet Corporation will post 3.92 EPS for the current fiscal year.

Insider Buying and Selling at Insulet

In other Insulet news, SVP John W. Kapples sold 5,278 shares of the business's stock in a transaction that occurred on Wednesday, May 14th. The shares were sold at an average price of $318.47, for a total transaction of $1,680,884.66. Following the completion of the transaction, the senior vice president now directly owns 23,180 shares in the company, valued at $7,382,134.60. The trade was a 18.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.39% of the company's stock.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.